Visterra(美國(guó))

Visterra

Visterrawww.visterrainc.comVisterra發(fā)現(xiàn)和開(kāi)發(fā)新型抗體應(yīng)對(duì)重大傳染病的預(yù)防和治療。Visterradiscoversanddevelopsnovelantibodiesforthepreventionandtreatmentofmajorinfectiousdiseases.Thecompany’sproprietaryantibodyengineer ingtechnologygeneratesuniquestructuralinformationthatidentifiesnoveltargetepitopes(sitesrecognizedbyantibodies)andguidesthedesignofantibodieswhichspecificallytargettheseepitopestoeffectivelycombatdisease.Thecompany’sleadantibodyproductcandidate,VIS410,isabroadspectrummonoclonalantibodyforthepreventionandtreatmentofbothseasonalandpandemicinfluenza.Thecompanyisbuildingaproprietarypipelineofnovelantibodiesininfectiousdisease,andcontinuingtoexpanditsdiseaseareafocusthroughstrategicpartnerships.VisterrawasfoundedbasedonscientificworkdevelopedinthelaboratoryofDr.RamSasisekharanandlicensedfromMIT.ThecompanyiscurrentlybackedbyPolarisPartners,